로딩 중…
StockDiggingStockDigging

휴마시스

205470· KOSDAQ
₩2,660-4.32%
2026-06-19

Price Chart

휴마시스-65.27%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap65.64B KRW
Revenue32.87B KRW
Net Income-16.75B KRW
Total Assets326.18B KRW
Net Assets235.48B KRW
Employees69
Value
P/B0.28x
P/S2.00x
Profitability
ROE-7.11%
ROA-5.14%
Op. Margin-28.74%
Revenue Growth44.76%
Financial Health
Debt Ratio138.51%
Total Debt13.19B KRW
Cash12.55B KRW
Current Ratio2.29x
Dividend
Div. Growth0.00%
Performance
1Y Return-65.27%
1M Return-35.83%
From 52W High-67.44%
1Y MDD-69.41%
Trading
Volume156,273 shares
Foreign Own.6.95%
Per Share
EPS-403 KRW
BPS9,612 KRW

Company Info

CEO 김성곤
Employees 69
Founded 2014
HQ 경기도 안양시, KR

Humasis, established in 2000 as a manufacturer of in-vitro diagnostic medical devices, was listed on the KOSDAQ market in 2017 after merging with HI No. 2 Special Purpose Acquisition Company. The company specializes in the development and production of POCT immunoassay reagent product lines. Through its subsidiary, Billionths, Humasis also manufactures condoms and medical rubber products and operates an entertainment business. It is pursuing business diversification by obtaining approval for new objectives like mineral development and sales at its 2024 regular general meeting of shareholders and is headquartered in Anyang-si, Gyeonggi-do.